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Abstract
Anorexia nervosa is considered the most deadly psychological illness. 
Individuals with and recovered from anorexia nervosa experience numerous physi-
cal and mental health difficulties, and treatment outcomes remain unpromising. 
Anorexia nervosa is rare in the general population, but common among individuals 
with a first-degree relative with the disorder. In addition, the onset of anorexia 
nervosa is developmentally specific, which suggests a partly biological etiology. 
A better understanding of the biological and neurobiological etiology of anorexia 
nervosa is direly needed to inform new therapies and to identify individuals at risk 
for the disorder. This paper summarizes the research related to neurotransmitter 
abnormalities, aberrant brain activity, and genetic and epigenetic mechanisms that 
may contribute to the etiology of this deadly disorder.
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1. Introduction
Anorexia nervosa (AN) is a serious psychological disorder characterized by low 
body weight, unhealthy weight loss methods, and an extreme focus on weight and 
body shape [1]. AN is associated with significant mortality risks due to medical com-
plications, as well as the fact that one in five patients with AN die by suicide [2, 3]. 
The physical sequelae of AN, which are caused by self-starvation, affect nearly every 
major organ system. For instance, the gastrointestinal complications of AN include 
dysphagia [4], delayed gastric emptying [5], and risk of gastric dilation or even per-
foration [6]. Hematological and musculoskeletal complications include osteoporosis, 
fracture risk [7], and low red and white blood cell counts [8]. The endocrine system 
is impacted via elevated cortisol and growth hormones, low serum thyroid levels, 
and hypoglycemia [5, 9]. Dermatological complications include lanugo, acrocyano-
sis, and thinning hair [10]. Neurological complications, which will be discussed in 
depth throughout this chapter, are well-documented in terms of the effects of long-
terms caloric restriction on brain volume and neural activity [11]. Finally, cardiac 
complications, which are most often linked to mortality in AN, include bradycardia 
[12], prolonged QTc interval [13], and left ventricular atrophy [14].
Current medication and psychotherapies have limited success in treating 
AN. The prognosis is especially poor if treatment begins more than 3 years after 
the onset of symptoms [15]. AN currently has no viable treatment options [16], as 
current medications and psychotherapies provide only minor to modest effects, 
with especially poor outcomes among women with entrenched AN [16–18]. It is 
estimated that only half of individuals with AN achieve full remission of symptoms, 
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and even recovered patients typically maintain a low weight and experience chronic 
depressive symptoms [19]. Given the lack of viable treatment options for AN, lead-
ing eating disorders researchers are now recommending that future research focus 
on identification of risk factors and other preventive strategies [20, 21].
Many of the identified risk factors for AN are biological or genetic in nature. 
AN is a rare disorder, with estimated lifetime prevalence ranging from 0.1 to 3.6%, 
and a point prevalence rate ranging from 0.1 to 1.2% in the general population [22]. 
Though the overall prevalence of AN is quite low, AN represents the third most 
common chronic illness with adolescent onset [23]. In addition, the risk of AN is 
elevated among individuals with a family history of AN. It is a well-documented 
finding that AN tends to run in families [24, 25]. Some studies have found a 10-fold 
risk of AN among first-degree relatives of individuals with the disorder [26–28] or 
an overall heritability of 0.56 [25]. Furthermore, AN has a developmentally specific 
age of onset. Taken together, these findings suggest the presence of biological and/
or genetic risk factors in the etiology of AN [29].
Individuals with AN often display a relentless pursuit of further weight loss and 
believe themselves to be overweight even when they are emaciated. In addition to 
pathological eating patterns, individuals with EDs also experience a host of unusual 
symptoms, such as “(1) extremes of behavioral inhibition and dysinhibition;  
(2) anxiety, depression, and obsessionality; and (3) puzzling symptoms such as body  
image distortion, perfectionism, and anhedonia” ([30], p. 38) as well as “intense 
body-focused anxiety, self-disgust, compulsive behavior and altered information 
processing—i.e. raised pain threshold, reduced sense of taste, anosognosia, inability 
to integrate thoughts and feelings, poor visuospatial memory, cognitive rigidity 
and weak central coherence” ([31], p. 580). Any biological mechanisms accounting 
for the inherent eating pathology of AN should also modulate these emotional and 
cognitive phenomena.
Identifying true risk factors for AN presents a complicated methodological 
problem. By definition, a risk factor must be present prior to the onset of illness, and 
identifying these factors prior to the symptom onset requires a prospective design 
[32]. However, given the low prevalence rate of AN, prospective studies are often 
too complicated to perform; thus, the research literature on AN risk factors is often 
limited to retrospective studies, with their inherent bias in retrospective recall [33].
Another methodological approach samples from individuals who have recovered 
from AN (RECAN). While recovery from AN is a long and ill-defined process, more 
than half of individuals with AN are able to completely or partly achieve remission 
[34]. Individuals RECAN are assumed to no longer be experiencing the sequelae of 
the starvation state. However, the use of individuals RECAN is limited as a method-
ological approach in that “scar” effects from a period of illness could be misidenti-
fied as premorbid risk factors [35]. In order to circumvent the possibility of “scar” 
effects, studies must identify endophenotypes that are present among individuals 
with active AN, individuals RECAN, and among unaffected family members [36, 37]. 
Utilizing this approach, several potential endophenotypes have been identified, by 
eliminating any neurobiological findings that improve with refeeding and identi-
fying abnormalities that are shared by individuals with AN and their unaffected 
family members [16].
Many of the neurobiological phenomena to be discussed in this paper are 
present premorbidly, exaggerated by malnutrition, and return to premorbid 
levels after recovery [38]. There are currently promising lines of research on 
dopaminergic [29], serotonergic [39], and noradrenergic pathways [31], as well 
as dysregulations in appetitive functioning [30], genetic and epigenetic contribu-
tions [40, 41], contributions from gonadal hormones [42], and aberrations in 
brain activity [43].
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2. Dopamine
Dopaminergic functioning modulates reward and affect, and an aberration in 
dopaminergic functioning has been implicated in obsessive or ritualistic behaviors, 
such as the food rituals observed in individuals with AN [29]. It seems intuitive 
that reward functioning is impaired in AN, as individuals with AN often pres-
ent as abstemious, anhedonic, and temperate in a multitude of behaviors even 
in childhood, long before the onset of symptoms [44]. Dopamine is central in 
processing reward in both primary and secondary reinforcers, including food 
[45–47]. Several research studies have revealed altered striatal dopamine function 
in individuals with and RECAN [29, 48, 49]. Ingestion of highly palatable foods, 
such as high-sugar foods, may trigger dopamine release in individuals without AN; 
this release of dopamine in response to food is similar to the release of dopamine 
elicited by amphetamine use, which is often associated with feelings of euphoria 
[50]. However, among individuals RECAN, amphetamine use triggers the expected 
endogenous dopamine release, but this release of dopamine is experienced as highly 
unpleasant and anxiogenic [51]. If similar processes take effect during exposure to 
highly palatable food, which would be experienced as highly anxiogenic to individ-
uals with AN, this could partially account for the persistence that individuals with 
AN display in their pursuit of self-starvation; if food is anxiogenic, self-starvation 
downregulates this anxiety. Whereas individuals without AN experience pleasure 
from foods, individuals with AN find it aversive. Thus, the reinforcing aspects of 
food are not experienced by individuals with active AN or individuals RECAN.
Reward processing in general appears to be altered in individuals with AN, even 
in situations that do not involve food- or weight-related cues. In fMRI research, 
individuals RECAN failed to differentiate between winning and losing money in a 
gambling task [52]. Therefore, individuals with AN may have a diminished ability 
to identify the positive or negative value of a stimulus. Individuals with AN fail 
to show appropriate appetitive motivational system activation to a variety of cues 
[49]. Thus, altered dopaminergic function reflects high conditioning of reward for 
disease-salient stimuli, but a failure to respond appropriately to other positive and 
negative cues [18].
Among individuals RECAN, dopamine metabolite concentrations in the cerebral 
spinal fluid remain depleted years after the disorder [53]. Perhaps to correct for 
this depletion, dopamine 2 and 3 (D2/D3) receptor binding in the ventral striatum 
is elevated among individuals RECAN [44]. At this time there are no publications 
on dopamine aberrations in unaffected family members. However, animal models 
of anorexia strongly suggest a dopaminergic endophenotype, as administering 
dopamine antagonists in activity-based anorexia in rats facilitates increased food 
intake [54]. This hints at a dopaminergic role in promoting weight loss, which can 
be reversed with psychopharmacology that acts on the dopamine system.
3. Serotonin
Additionally, serotonergic (5-HT) dysfunction may be a biological marker 
for AN. Serotonin has seemed a likely candidate for some time, given this neu-
rotransmitter’s active influence in modulating mood and appetite [29]. A recent 
meta-analysis has concluded that being a carrier of the S allele of the 5-HTTLPR 
polymorphism of the serotonin transporter gene is predictive of eating disorders, 
particularly anorexia [55]. The gene coding of the serotonin transporter (5-HTT) 
works in the presynaptic neuron to terminate serotonin activity in the synapse and 
recycle serotonin back into the presynaptic neuron. 5-HTT is coded by a gene on 
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chromosome 17, and the 5-HTTLPR polymorphism of this gene has the greatest 
impact on behavior. The S allele is a short variant of this 5-HTTLPR polymorphism, 
which decreases the availability of 5-HTT and results in dysphoria.
In terms of appetite, any treatment that increases intrasynaptic 5-HT or activates 
5-HT receptors will reduce appetite and food consumption, while any treatment that 
reduces transmission or blocks receptors will promote weight gain [56]. Caloric restric-
tion has an enormous impact on the available serotonin in the brain [29]. Tryptophan is 
one of 20 essential amino acids and can be absorbed only through caloric intake, espe-
cially carbohydrate intake [57]. Tryptophan, through a series of chemical processes, 
becomes serotonin. A restricted diet limits the amount of tryptophan (and, therefore, 
the amount of serotonin) that is available to the brain [58]. In addition, a restricted 
diet decreases the rate of synthesis in serotonin receptors and the density of serotonin 
transporters, which results in oversensitivity to serotonin in postsynaptic receptors 
[59]. Not surprisingly, individuals in the acutely ill state have lowered concentrations 
of the 5-HT metabolite 5-HIAA in the cerebral spinal fluid [56]. However, elevated 
levels of 5-HIAA were likely present premorbidly. Individuals with AN premorbidly 
report high levels of anxiety, dysphoria, and obsessionality, which are associated with 
high levels of 5-HT in the synapse [42]. Dieting actually serves to regulate the 5-HT 
in the synapse. This reduction of serotonin, in the short term, results in anxiolytic 
effects for people who restrict calories [29]. These anxiolytic effects could explain why 
individuals with AN cling so desperately to their restrictive behaviors: these behaviors 
are inadvertently medicating underlying anxiety.
The serotonin system includes at least 14 different receptors. The 5-HT1A and 
5-HT2A receptors appear most influential in the pathogenesis of AN. The 5-HT1A 
autoreceptor serves to decrease 5-HT transmission [56]. Individuals with AN have 
50–70% more binding at these receptors, and retain 20–40% more binding after 
recovery. In addition, the 5-HT1A receptor may play a role in the efficacy of selective 
serotonin reuptake inhibitors (SSRIs), which are potently effective at treating depres-
sion and anxiety [60, 61]. While starvation decreases 5-HT across the brain, the 
overactive 5-HT1A receptor continues to inhibit 5-HT transmission. The combination 
of these forces is so powerful that SSRIs exert minimal impact in increasing intrasyn-
aptic 5-HT, which fails to provide symptom relief for individuals with AN [56]. In AN, 
SSRIs fail to desensitize 5-HT1A receptors, which inhibits presynaptic 5-HT.
Newer imaging technologies, such as PET imaging with selective neurotransmit-
ter radioligands, allow for viewing in vivo neurotransmitter activity in the brain. 
Postsynaptic 5-HT2A receptors have been studied in this way. The 5-HT2A receptor has 
been afforded special attention because activity at this receptor is influential in two of 
the central, yet most perplexing, symptoms of AN: poor problem-solving abilities and 
distorted body image [62, 63]. 5-HT2A receptor binding is reduced in several brain 
areas, especially in the cingulate and temporal regions. The cingulate-temporal dys-
function could be related to inefficient problem-solving behaviors among individuals 
with AN, who struggle with incorporating affective and social stimuli into tasks [64]. 
Individuals with AN do not seem to learn from mistakes, but stubbornly and obses-
sively use the same strategies, despite poor results. This could indicate dysfunction 
in executive functioning and planning. In terms of distorted body image, which is 
characterological for individuals with AN, 5-HT2A disturbances in the left parietal 
region of the brain are thought to be responsible [62]. Lesions in the right parietal 
region have been associated with neglect, which could be theoretically related to body 
image distortion, especially if this information is coded in the parietal regions of each 
hemisphere [56]. The activity at 5-HT2A receptors remains dysregulated even after 
a year of maintaining normal weight, regular menstruation, and no binge/purging/
restricting. Prolonged dysregulation at these receptors may partially account for the 
inefficacy of SSRIs in treating AN, regardless of the phase of the disorder [17, 18].
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Additionally, serotonergic dysfunction is common to other psychiatric concerns, 
especially those that are likely to be comorbid with AN, such as major depression 
[65] and anxiety disorders [66]. While abnormalities in serotonergic functioning 
are common to all of these disorders, different patterns of serotonergic functioning 
emerge on a molecular level [67]. While 5-HT1A receptor binding is often decreased 
in individuals with or recovered from depression [68, 69] and panic disorder [70], 
5-HT1A receptor binding is increased in individuals with AN [29]. This could indicate 
that serotonergic dysfunction is a common vulnerability for a variety of disorders, 
with disorder-specific patterns at the neuronal level. This also accounts for higher 
rates of psychiatric concerns among family members of individuals with AN.
Given etiological research on the separate roles of dopamine and serotonin, it 
is not surprising that the most recent research suggests that interactions between 
serotonin and dopamine activity truly elicit and maintain the eating pathology of 
AN [56]. This interaction is not well understood, but could hold promise for future 
pharmacological interventions for AN.
4. Norepinephrine
Based on previous research on dopaminergic and serotonergic dysfunction in 
individuals with active AN, individuals RECAN, and unaffected family members, 
it is safe to conclude that neurotransmitter activity is aberrant both during the 
premorbid, active, and recovery periods of AN. Dopaminergic and serotonergic 
pathways could account for some, though not all, of the core symptoms of AN [29, 42]. 
While these pathways (particularly the serotonergic pathway) partly account for 
rigidity and perfectionism among individuals with AN, individuals with AN display 
a variety of perplexing symptoms that seem unrelated to both the starvation state 
itself or serotonin dysfunction alone; individuals with AN report difficulty with 
pain perceptual, alexithymia, reduced sense of taste, as well as numerous other 
perplexing symptoms [31]. Aberrant activity in the noradrenergic pathway could 
better account for this vast range of deficits.
Norepinephrine is a neurotransmitter which serves multiple functions in the 
body and brain, including regulation of sympathetic arousal/anxiety and cerebral 
blood flow [71]. Norepinephrine levels are elevated premorbidly in AN [72], but 
appear to be decreased in plasma and cerebrospinal fluid during active AN ad 
RECAN [72–74]. Premorbidly high levels of norepinephrine lead to high sympa-
thetic arousal and anxiety [31]. Among individuals with AN, this anxiety is often 
focused on food- and weight-related issues, though the inherently high trait levels 
of perfectionism and neuroticism can manifest in other achievement domains such 
as schoolwork or sports [75]. Since this anxiety is linked an abundance of norepi-
nephrine, dieting in the early stages of AN counteracts this by depleting the brain 
of the precursors to norepinephrine that are normally ingested through food [31]. 
Dieting is then maintained through negative reinforcement, leading to a reduction 
in body weight and entrenchment of AN symptoms. Furthermore, aberrant activity 
in the noradrenergic system has been linked to irregular patterns of activation in the 
insula, which will be discussed in the next section.
5. Brain volume, blood flow, and neural activity
Various neuroimaging studies show substantial structural abnormalities in the 
brain among individuals with active AN [30, 76, 77]. However, significant questions 
remain as to:
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whether such anomalies reflect regionally specific disturbances that might help 
explain disorder-defining psychopathology or merely generic, global consequences 
of malnutrition. Similarly, it remains unclear whether structural alterations in AN 
constitute premorbid traits or persisting “scars,” as might be the case if they would 
still be evident following weight restoration ([76], p. 214).
Decreased volumes of white and gray brain matter have been documented 
throughout the brain during the acute phases of illness [77, 78]. More specifically, 
gray matter atrophy has been noted in the cerebellum, hypothalamus, caudate 
nucleus and frontal, parietal and temporal areas [77, 79, 80], as well as in the 
cingulate cortex [81] and the precuneus [82]. The rate of gray matter atrophy is 
not uniform across the brain during active AN; atrophy in the hypothalamus may 
appear early in AN, whereas atrophy in the cerebellum is a late consequence of AN 
among patients with longer durations of illness [77].
However, these gray and white matter findings appear to be specific to the acute 
phase of illness and caused by malnutrition and cerebral dehydration [77]. A meta-
analysis revealed that gray matter is reduced by 5.6% during the acute phases of AN, 
whereas white matter is reduced by 3.8% [83]. A few months of treatment and results 
in approximately 50% of gray matter regain and nearly all of the white matter being 
regained. A few years following remission of AN, gray matter and white matter deple-
tions are no longer statistically significant. It is possible that hormone levels impact 
how much gray matter is recovered, as high levels of cortisol at the time of hospital-
ization are negatively correlated with gray matter restoration following weight gain 
[84]. All told, the decreased volume of white and gray matter in individuals with AN 
normalizes with proper nutrition [38, 85]. Thus, these gray and white matter findings 
are not likely to be a contributing factor to the neurobiological etiology of AN.
In contrast, abnormal patterns of blood flow to the brain and brain activity 
persist after recovery. For instance, individuals who have recovered from AN often 
have hypoperfusion in the frontal, parietal, temporal and occipital areas of the 
brain [86]. In addition, overactivation of the frontal and anterior cingulate cortex 
(ACC) and insula following exposure to pictures of food or the taste of food is 
present both during active AN and after recovery [87, 88]. Hyperactivity in these 
regions could be an endophenotype for AN and be related to more global difficulties 
with appetitive mechanisms.
The complex eating pathology inherent in AN may indicate atypical function-
ing in appetitive mechanisms. Despite the unique and stereotypic presentation 
of altered eating patterns in the eating disorder diagnoses, it is still unknown 
whether individuals with AN have disordered appetitive functioning. The neural 
and limbic circuits are more likely candidates for deregulating appetitive function-
ing in AN than peripheral signs (such as hormonal imbalances or abnormalities in 
the gastrointestinal tract), because these neural and limbic circuits also regulate 
reward processing and emotionality, which are known to be disordered in AN [89]. 
Individuals with AN display an almost phobic avoidance of high-fat foods, which 
persists after recovery. Individuals who have recovered from AN fail to connect 
hunger cues with positive ratings of food [88]. Particularly promising research has 
focused specifically on the anterior insula, which is positioned in the primary gusta-
tory cortex [90]. While this is still debated, researchers posit that the anterior insula 
codes a representation of food and its hedonic value, and projects to other parts 
of the brain [91, 92]. The anterior insula resides next to the orbito-frontal cortex, 
which interprets information from the anterior insula and is responsible for flexible 
decision-making with ever-changing stimuli [93]. Put another way, the anterior 
insula represents the food and its hedonic value, while the orbito-frontal cortex 
weighs those representation against hunger and other variables. Critically, the 
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orbito-frontal cortex is very sensitive to changes in serotonin, which could account 
for the inflexibility in eating pathology in individuals with AN [94]. Even though 
research in this area is still in its infancy, the aforementioned processing abnormali-
ties in the anterior insula and orbito-frontal cortex shed some light as to how “AN 
individuals fail to become appropriately hungry when starved, and thus are able to 
become emaciated” ([30], p. 45).
Though disturbances related to the gustatory modulation of the anterior insula 
certainly appear to be a key part of a biological risk factor in AN, the anterior insula 
influences many processes unrelated to gustatory mechanisms [30]. Disturbances in 
the anterior insula could be related to a more general deficit in interoceptive aware-
ness [95, 96]. Altered activity in the insula “supports the idea that they might suffer 
from a fundamentally and physiologically altered sense of self” ([97], p. 111). Some 
of the more mysterious symptoms of AN, such as a denial of signs of malnutrition 
and lack of motivation to change pathological eating behaviors, could be linked to 
abnormal patterns of activity in the insula [98].
6. Genetics
There is clear and compelling evidence that having a first-degree relative with 
AN significantly elevates one’s risk for developing AN; in fact, relatives of individu-
als with AN are 11.3 times more likely to develop AN [27]. There is likely some 
genetic contribution to the etiology of AN. Current heritability estimates range 
between 50 and 80% [99, 100], though specific genetic mechanisms have been dif-
ficult to identify. A noteworthy paradox was pointed out regarding the high heri-
tability of AN and the likelihood of reduced reproductive fitness from prolonged 
periods of malnutrition [101]. Thus, one can conclude that genes that contribute 
to the etiology of AN must be rare and of recent origin. In addition, high rates of 
diagnostic crossover between eating disorder categories (see [102]) and high rates 
of comorbidity with mood and anxiety disorders (see [103]) also complicate the 
genetic etiology of AN, since any genetic predispositions for AN should be non-
specific and shared with these other conditions.
One method of identifying genes relevant to the pathophysiology of AN is the 
candidate gene approach. The candidate gene approach is defined as an examina-
tion of genes that could be involved in a particular disease or syndrome because the 
function of those genes is related to the sequelae of the illness [104]. The candidate 
gene approach could be likened to finding “a needle in the haystack” of 27,000 
human genes. Thus, it is not surprising that candidate gene studies for AN are 
controversial and many fail to replicate genetic association.
Family-based linkage analyses, or the process of detecting the location of 
disease genes on the chromosome, have identified three chromosomal regions of 
interest for AN; one resides on chromosome 13 (specifically, 13q13.3) and is related 
to drive-for-thinness, another resides on chromosome 2 (2p11.2) and is related to 
obsessionality, and a third on chromosome 1 (specifically, 1q1.3) which is related to 
both obsessionality and drive-for-thinness [105].
Genes related to dopamine transfer (DAT1) and dopamine receptors (DRD2) 
have been examined among patients with AN. Individuals with AN show elevated 
expression of DAT1 and reduced expression of DRD2 [106]; while the implications 
of these expression are not fully understood, a genetic contribution to the etiology 
of AN related to dopamine expression is consistent with previously mentioned 
research on altered reward processing in AN. Other genetic research has also 
identified an interaction of three genes that clear serotonin and norepinephrine 
from the synapse; these genes (a serotonin transporter gene, a norepinephrine 
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transporter gene, and a monoamine oxidase A gene) appear to contribute to the risk 
of restricting AN [41]. While the presence of each gene variant alone is associated 
with a somewhat increased risk of restricting AN, the combination of all three gene 
variants leads to a risk that is up to eight times greater than the risk associated with 
one gene variant alone.
Finally, there are epigenetic factors to consider. Perhaps the most important epi-
genetic mechanism to consider is the role of estradiol in triggering genetic risk for 
AN, which is discussed below. All told, the genetic and epigenetic contributions to 
AN remain largely unknown. Genetic studies are limited by previously mentioned 
methodological issues, such as the low prevalence of AN and the near impossibility 
of recruiting individuals with AN during the premorbid period for genetic research. 
However, progress in identifying genes or patterns of gene expression could lead to 
pharmacological advances that are direly needed for this population given the poor 
response to common psychotropics such as selective serotonin reuptake inhibitors, 
tricyclic antidepressants, and antipsychotics [17, 18].
7. Pubertal hormones
The vast majority of individuals with AN are biologically female and begin 
experiencing symptoms of AN during the pubertal and pre-pubertal periods of 
development [1]. These findings suggest that gonadal hormones specific to females 
may play a role in the epigenesis of AN. It is possible that genetic factors may be 
more impactful for females than males with regards to drive for thinness and body 
dissatisfaction [107] as well as for concerns about body shape and weight [108]. In 
addition to gender differences in genetic factors, genetic risk for eating disorders 
appears to be moderated by age, as there is almost no genetic effect (5% or less 
on disordered eating among preadolescent female twins, but by late adolescence 
there is evidence of substantial genetic effects [109]. Upon closer examination, the 
genetic effect appears to be due to pubertal status and not age, as 11-year-old twins 
who had begun puberty showed a higher magnitude of genetic effects compared 
to same-age twins who had not begun puberty [110]. Pubertal hormones, such as 
estradiol, which steadily increases during puberty among females, may trigger the 
genetic risk for disordered eating, as high levels of estradiol are associated with 
magnitude of genetic effects in a manner independent of age and physical signs of 
puberty development, such as body hair or breast development [111].
In addition to triggering the genetic risk for AN, low estradiol levels are associated 
with a number of negative effects during the active phases of AN. Not surprisingly, 
malnourished individuals show a variety of hormonal imbalances, most of which return 
to baseline after recovery [42]. Pubertal hormones appear to follow this same pattern of 
alteration during active illness but return to baseline upon weight regain. In a typically 
developing adolescent, an increase in pubertal hormones aids in brain maturation, 
most notably in the limbic system [112, 113]. These hormone levels are altered among 
individuals diagnosed with AN, who may experience amenorrhea due to low body 
weight and/or body fat [114]. When individuals achieve weight regain and recommence 
with menstruation, cognitive functioning improves, suggesting that increasing levels of 
estradiol during weight regain may assist with neural recovery [115].
8. Conclusions and future directions
The etiology of AN is multifaceted, with contributions from genetic factors, 
biological factors, family dynamics, personality characteristics, and sociocultural 
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influences. The development of this disorder and its maintenance remain poorly 
understood despite a significant increase in rigorous scientific study into risk factors 
and shared vulnerabilities with other eating disorders and psychological disorders.
In recent years, the neurobiological etiology of AN has been examined through a 
wide variety of imaging studies, genetic studies, and hormonal/biological studies (see 
[97]). A number of key findings are summarized in this paper. Across these studies, it is 
clear that the brains of individuals with AN show evidence of altered reward processing 
and appetitive mechanisms, which are linked to a number of dopaminergic findings 
(perhaps, most importantly, how the brains of individuals with AN process cues of 
palatable foods as highly anxiogenic and aversive [50, 51]. Serotonergic functioning has 
been long-thought to account for behavioral rigidity and trait obsessionality in AN [56], 
and recent genetic research has identified a number of potential serotonergic genetic 
candidates or interactions of genetic candidates that represent significant risk factors 
for AN [44, 74, 104, 107]. Finally, altered noradrenergic functioning and aberrant activ-
ity in the insula represent a unique but comprehensive view of the global difficulties 
individuals with AN have with emotions, insight, and interoceptive awareness [31, 71].  
These findings, taken together, can illuminate future pathways for pharmacotherapies 
that will be more effective for individuals with AN. Other brain-based findings dis-
cussed in this paper, such as gray and white matter atrophy, are unlikely to represent 
true risk factors, because the vast majority improve with proper nutrition.
In conclusion, the neurobiological etiology of AN in-and-of-itself is complex and 
complicated by factors such as the low prevalence rate of AN [1], lack of prospective 
research [32], and the at-times catastrophic impact of malnutrition on the brain and 
body [38]. AN continues to be considered the most deadly psychological illness, and 
individuals RECAN may face a lifetime of physical and emotional challenges [1]. 
Given the ego-syntonic nature of this disorder and that current treatment outcomes 
are suboptimal for this population, a better understanding of the biological vulner-
abilities of this illness and the development of new therapies are direly needed.
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